<VariationArchive RecordType="classified" VariationID="811885" VariationName="NM_000297.4(PKD2):c.654_655del (p.Ser219fs)" VariationType="Deletion" Accession="VCV000811885" Version="8" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-06" DateCreated="2020-02-10" MostRecentSubmission="2020-02-10">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="799376" VariationID="811885">
      <GeneList>
        <Gene Symbol="PKD2" FullName="polycystin 2, transient receptor potential cation channel" GeneID="5311" HGNC_ID="HGNC:9009" Source="calculated" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>4q22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="88007635" stop="88077777" display_start="88007635" display_stop="88077777" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="88928798" stop="88998930" display_start="88928798" display_stop="88998930" Strand="+" />
          </Location>
          <OMIM>173910</OMIM>
          <Haploinsufficiency last_evaluated="2012-07-06" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PKD2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2012-07-06" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PKD2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000297.4(PKD2):c.654_655del (p.Ser219fs)</Name>
      <CanonicalSPDI>NC_000004.12:88019513:AAAA:AA</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>4q22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="88019514" stop="88019515" display_start="88019514" display_stop="88019515" variantLength="2" positionVCF="88019513" referenceAlleleVCF="TAA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="88940666" stop="88940667" display_start="88940666" display_stop="88940667" variantLength="2" positionVCF="88940665" referenceAlleleVCF="TAA" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>S219fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.88940668_88940669del" Assembly="GRCh37">
            <Expression>NC_000004.11:g.88940668_88940669del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.12" sequenceAccession="NC_000004" sequenceVersion="12" change="g.88019516_88019517del" Assembly="GRCh38">
            <Expression>NC_000004.12:g.88019516_88019517del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008604.1" sequenceAccession="NG_008604" sequenceVersion="1" change="g.16849_16850del">
            <Expression>NG_008604.1:g.16849_16850del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000297.4" sequenceAccession="NM_000297" sequenceVersion="4" change="c.654_655del" MANESelect="true">
            <Expression>NM_000297.4:c.654_655del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000288.1" sequenceAccession="NP_000288" sequenceVersion="1" change="p.Ser219fs">
            <Expression>NP_000288.1:p.Ser219fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_156488.2" sequenceAccession="NR_156488" sequenceVersion="2" change="n.753_754del">
            <Expression>NR_156488.2:n.753_754del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1578118330" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000297.4(PKD2):c.654_655del (p.Ser219fs) AND Polycystic kidney disease 2" Accession="RCV001002340" Version="8">
        <ClassifiedConditionList TraitSetID="3718">
          <ClassifiedCondition DB="MedGen" ID="C2751306">Polycystic kidney disease 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-01-23" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-01-23" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-02-10" MostRecentSubmission="2020-02-10">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="3718" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6943" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Polycystic kidney disease 2</ElementValue>
                <XRef ID="MONDO:0013131" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY DISEASE, ADULT, TYPE II</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY DISEASE 2 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">APKD2</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PKD2</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Autosomal dominant polycystic kidney disease (ADPKD) is generally a late-onset multisystem disorder characterized by bilateral kidney cysts, liver cysts, and an increased risk of intracranial aneurysms. Other manifestations include: cysts in the pancreas, seminal vesicles, and arachnoid membrane; dilatation of the aortic root and dissection of the thoracic aorta; mitral valve prolapse; and abdominal wall hernias. Kidney manifestations include early-onset hypertension, kidney pain, and kidney insufficiency. Approximately 50% of individuals with ADPKD have end-stage kidney disease (ESKD) by age 60 years. The prevalence of liver cysts increases with age and occasionally results in clinically significant severe polycystic liver disease (PLD), most often in females. Overall, the prevalence of intracranial aneurysms is fivefold higher than in the general population and further increased in those with a positive family history of aneurysms or subarachnoid hemorrhage. There is substantial variability in the severity of kidney disease and other extra-kidney manifestations.</Attribute>
                <XRef ID="NBK1246" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301424</ID>
                <ID Source="BookShelf">NBK1246</ID>
              </Citation>
              <XRef ID="C2751306" DB="MedGen" />
              <XRef ID="MONDO:0013131" DB="MONDO" />
              <XRef Type="MIM" ID="613095" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2284828" SubmissionDate="2019-08-05" DateLastUpdated="2020-02-10" DateCreated="2020-02-10">
        <ClinVarSubmissionID localKey="2222371|OMIM:613095" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV001160244" DateUpdated="2020-02-10" DateCreated="2020-02-10" Type="SCV" Version="1" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-01-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The PKD2 c.654_655delAA; p.Ser219fs variant, to our knowledge, is not reported in the medical literature or gene specific databases. This variant is also absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. This variant causes a frameshift by deleting 2 nucleotides, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/w2yp3qyt/arup_molecular_germline_variant_investigation_process.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000004.11:g.88940668_88940669delAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613095" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Aug 2019 ARUP</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2284828" TraitType="Disease" MappingType="XRef" MappingValue="613095" MappingRef="OMIM">
        <MedGen CUI="C2751306" Name="Polycystic kidney disease 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

